This project aims to advance a new asexual blood-stage malaria vaccine candidate, based on the PfRipr5 protein of the malaria parasite....

This work paved the way for the clinical development of a vaccine against placental malaria.

EVI supports new EC-funded project that aims to strengthen international research and innovation cooperation between China and the EU

TRANSVAC2 project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines.

CEPI awards contract worth up to US$ 31 million to develop vaccine against Nipah virus.

Workshop will concentrate on latest advances in non-invasive imaging technologies.

3rd Call for TRANSVAC Training Modules now advertised.

The Multi-Stage Malaria Vaccine Consortium (MMVC) offers 3 PhD Fellowships in Malaria Research.

EVI-supported project publishes first clinical results for vaccine candidate to prevent pregnancy-associated malaria.

European Commission highlights that EU-funded TRANSVAC2 project.

Deadline for submission: 7 March 2019, 16:00 (GMT)

New article published on in npj Vaccines

The annual meeting of the GHIT-funded SEmalvac2 and SEmalvac projects was successfully held on 29-30 May in Ouagadougou, Burkina Faso.

The European and African partners of the EDCTP-funded project PREV_PKDL met at the University of York (United Kingdom) on 07-08 June 2018.

EVI and Processing personal data on the basis of the EU/EEA General Data Protection Regulation.

Phase II clinical trials in Sudan of a therapeutic vaccine to prevent post kala azar dermal leishmaniasis to be supported by EDCTP.

EVI's 20th Anniversary Symposium will take place on 20-21 November 2018 in Heidelberg, Germany.

On the 10th anniversary of the Word Malaria Day, EVI announces that two malaria vaccine candidates have made important progress.

This short movie explains you what the whole initiative is about.

VAC2VAC project recommendations published in Biologicals.

EVI’s financial reporting is now streamlined and more efficient.

The first annual meeting of the EU-funded project ZIKAVAX took place on 7 December 2017 at CEA, Fontenay-aux-Roses, France.

EDCTP funded MVVC2 study published today in Frontiers in Immunology.